Downstream Issues Still Beset Production
To Protect the Bottom Line, Biomanufacturers Invest in Downstream Purification Technology
GEN Roundup: No Detail Is Too Small in Bioprocess Scaleup
A Change in Scale Can Change Everything
Amid Election Clamor, Research Issues Surface
Sounds of Science Podcast
10 Takeover Targets of 2016
Which Biopharmas Do Wall Street Watchers View As Top Buyout Candidates?
Blockbuster Drugs: Endangered Species?
Our list of top-selling drugs of the 21st century shows how much money those drugs made between 2000 and 2011; the total amounts for all of them are in the billions. However, given the advent of personalized medicine and the increasing number of biosimilars entering the market, will pharmaceutical giants be able to maintain that level of success, or does our list contain the last of the blockbusters?